Language
EyePoint Pharmaceuticals misses top and bottom line estimates (NASDAQ:EYPT)

News

HomeHome / News / EyePoint Pharmaceuticals misses top and bottom line estimates (NASDAQ:EYPT)
search
RECENT NEWS

Aug 14, 2023

Adding art to downtown Derry

Aug 08, 2023

Vegan Memphis

Aug 06, 2023

Adam Brody on ‘F—ing Boring’ Method Acting and His Failed ‘Guardians of the Galaxy’ Audition: ‘I Wanted That One’

Jul 25, 2023

Barrier

Aug 16, 2023

Paint recycling

SEND YOUR INQUIRY
SUBMIT

Nov 01, 2023

EyePoint Pharmaceuticals misses top and bottom line estimates (NASDAQ:EYPT)

Net product revenue for the second quarter was $5.3 million, compared to net product revenues for the second quarter ended June 30, 2022 of $11.3 million. The decline in net product revenue resulted

Net product revenue for the second quarter was $5.3 million, compared to net product revenues for the second quarter ended June 30, 2022 of $11.3 million. The decline in net product revenue resulted from the sale of the YUTIQ franchise in May 2023 and the discontinuation of DEXYCU sales activities in 2023.

Net revenue from royalties and collaborations for the second quarter ended June 30, 2023 totaled $3.8 million compared to $0.3 million in the corresponding period in 2022.

Cash and investments at June 30, 2023 totaled $142.5 million compared to $144.6 million at December 31, 2022.

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Have a tip?